Literature DB >> 25754171

Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in medicare patients.

Viktor V Chirikov1, Fadia T Shaya1,2, Charles D Howell3.   

Abstract

UNLABELLED: Patient- and county-level characteristics associated with advanced liver disease (ALD) at hepatitis C virus (HCV) diagnosis were examined in three Medicare cohorts: (1) elderly born before 1945; (2) disabled born 1945-1965; and (3) disabled born after 1965. We used Medicare claims (2006-2009) linked to the Area Health Resource Files. ALD was measured over the period of 6 months before to 3 months after diagnosis. Using weighted multivariate modified Poisson regression to address generalizability of findings to all Medicare patients, we modeled the association between contextual characteristics and presence of ALD at HCV diagnosis. We identified 1,746, 3,351, and 592 patients with ALD prevalence of 28.0%, 23.0%, and 15.0% for birth cohorts 1, 2, and 3. Prevalence of drug abuse increased among younger birth cohorts (4.2%, 22.6%, and 35.6%, respectively). Human immunodeficiency virus coinfection (prevalence ratio [PR] = 0.63; 95% confidence interval [CI]: 0.50-0.80; P = 0.001), dual Medicare/Medicaid eligibility (PR = 0.89; 95% CI: 0.80-0.98; P = 0.017), residence in counties with higher median household income (PR = 0.82; 95% CI: 0.71-0.95; P = 0.008), higher density of primary care providers (PR = 0.84; 95% CI: 0.73-0.98; P = 0.022), and more rural health clinics (PR = 0.90; 0.81-1.01; P = 0.081) were associated with lower ALD risk. End-stage renal disease (PR = 1.41; 95% CI: 1.21-1.63; P = 0.001), alcohol abuse (PR = 2.57; 95% CI: 2.33-2.84; P = 0.001), hepatitis B virus (PR = 1.32; 95% CI: 1.09-1.59; P = 0.004), and Midwest residence (PR = 1.22; 95% CI: 1.05-1.41; P = 0.010) were associated with higher ALD risk. Living in rural counties with high screening capacity was protective in the elderly, but associated with higher ALD risk among the disabled born 1945-1965.
CONCLUSIONS: ALD prevalence patterns were complex and were modified by race, elderly/disability status, and the extent of health care access and screening capacity in the county of residence. These study results help inform treatment strategies for HCV in the context of coordinated models of care.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25754171     DOI: 10.1002/hep.27775

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  3 in total

1.  Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas.

Authors:  Channa R Jayasekera; Ryan B Perumpail; David T Chao; Edward A Pham; Avin Aggarwal; Robert J Wong; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2015-12       Impact factor: 3.199

2.  Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States.

Authors:  Channa R Jayasekera; Rachel Beckerman; Nathaniel Smith; Ryan B Perumpail; Robert J Wong; Zobair M Younossi; Aijaz Ahmed
Journal:  J Clin Transl Hepatol       Date:  2017-02-02

3.  Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017.

Authors:  Ping Du; Xi Wang; Lan Kong; Thomas Riley; Jeah Jung
Journal:  Am J Prev Med       Date:  2020-11-19       Impact factor: 5.043

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.